ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Efficacy"

  • 2018 American Transplant Congress

    Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients

    E. Loncharic, A. Dodson, K. Gutierrez.

    Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.

    Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…
  • 2018 American Transplant Congress

    Long-Term Efficacy and Safety of Prolonged-Release Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate-Release Tacrolimus

    N. Undre,1 J. Rubik,2 D. Debray,3 D. Kelly,4 F. Iserin,5 N. Webb,6 P. Czubkowski,2 K. Vondrak,7 A-.L. Sellier-Leclerc,8 S. Riva,9 B. Tönshoff,10 L. D'Antiga,11 S. Marks,12 R. Reding,13 G. Kazeem.1

    1Astellas Pharma Europe Ltd, Chertsey, United Kingdom; 2Children's Memorial Health Institute, Warsaw, Poland; 3APHP-Hôpital Universitaire Necker, Paris, France; 4Birmingham Children's Hospital, Birmingham, United Kingdom; 5University Hospital Necker Enfants Malades, Paris, France; 6Manchester University Foundation Trust, Manchester, United Kingdom; 7University Hospital Motol, Prague, Czech Republic; 8Hôpital Femme-Mère-Enfant, Bron Cedex, France; 9ISMETT-IRCCSS, Palermo, Italy; 10University Children's Hospital, Heidelberg, Germany; 11Hospital Papa Giovanni XXIII, Bergamo, Italy; 12Great Ormond Street Hospital for Children, London, United Kingdom; 13Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium.

    Study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) in stable solid organ allograft recipients (aged 5–16 yrs) who participated in a multicenter, Phase II pharmacokinetics…
  • 2018 American Transplant Congress

    Immunoglobulin Replacement Therapy in Pediatric Renal Transplant Patients

    A. Lewis, M. Fasano, D. Zepeda-Orozco.

    University of Iowa Hospitals and Clinics, Iowa City, IA.

    Immunoglobulin replacement therapy decreases infection frequency in patients with primary immunodeficiency; however, there is limited data regarding the use of intravenous immunoglobulin (IVIG) or subcutaneous…
  • 2018 American Transplant Congress

    Efficacy and Safety of Immediate- and Prolonged-Release Tacrolimus in De Novo Pediatric Transplantation: Randomized Study

    K. Vondrak,1 F. Parisi,2 A. Dhawan,3 R. Grenda,4 N. Webb,5 S. Marks,6 D. Debray,7 R. Holt,8 A. Lachaux,9 D. Kelly,10 G. Kazeem,11 N. Undre.11

    1University Hospital Motol, Prague, Czech Republic; 2Osp Pediatrico Bambino Ges[ugrave], Rome, Italy; 3King's College Hospital, London, United Kingdom; 4The Children's Memorial Health Institute, Warsaw, Poland; 5Manchester University Foundation Trust, Manchester, United Kingdom; 6Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom; 7APHP-Hôpital Universitaire Necker, Paris, France; 8Alder Hey Children's Hospital, Liverpool, United Kingdom; 9Université Lyon 1 et Hospices Civils de Lyon, Lyon, France; 10Birmingham Children's Hospital, Birmingham, United Kingdom; 11Astellas Pharma Europe Ltd, Chertsey, United Kingdom.

    This study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) vs immediate-release tacrolimus (IR-T) in de novo pediatric transplant pts. Phase II, parallel-group, multicenter, open-label study…
  • 2018 American Transplant Congress

    Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study

    S. Mulgaonkar,1 Y. Qazi,1 D. Kim,1 V. Peddi,1 K. McCague,2 D. Patel,2 A. Wiseman.1

    1TRANSFORM Study Group, Livingston; 2Novartis Pharmaceuticals Corporation, East Hanover.

    Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…
  • 2018 American Transplant Congress

    Immunogenic HLA Mismatches and Evidence That Belatacept May Be the First Therapy Able to Prevent DQ De Novo DSA: An Analysis of the BENEFIT and BENEFIT-EXT Trial Cohorts

    M. Everly,1 V. Jucaud,1 M. Roberts,2 H. Gebel,3 R. Bray.3

    1Terasaki Research Institute, Los Angeles, CA; 2Immunology Biomarker Group, Bristol-Myers Squibb, Princeton, NJ; 3Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.

    The use of belatacept over cyclosporine is associated with lower rates of DSA development in adult kidney transplantation. However, the effect of belatacept on the…
  • 2018 American Transplant Congress

    Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies

    F. Shihab,1 Y. Qazi,1,2 V. Peddi,1 D. Shaffer,1 D. Kim,1,2 K. McCague,3 D. Patel,3 S. Mulgaonkar.1,2

    1US92 Study Group, Salt Lake City; 2TRANSFORM Study Group, East Hanover; 3Novartis Pharmaceuticals Corporation, East Hanover.

    Purpose: Attainment of everolimus (EVR) target trough level (C0 3-8ng/mL) is crucial in achieving comparable efficacy-safety with EVR+reduced (r) calcineurin inhibitor regimen (CNI; tacrolimus [TAC]…
  • 2018 American Transplant Congress

    A Novel Combined Formula to Direct Optimal Immunosuppressive Drug Exposure in Renal Transplant Recipients

    O. Pankewycz,1 E. Onan,2 M. Laftavi,1 R. Gruessner,3 H. Smileuski,1 E. Alissandrello,1 A. Gruessner.3

    1Upstate Medical University, Syracuse, NY; 2Cukurova University, Adana, Turkey; 3Downstate Medical University, New York, NY.

    Purpose: The most widely used maintenance immunosuppressive combination after kidney transplantation is tacrolimus (TAC) and mycophenolic acid (MPA). The utility of therapeutic drug monitoring for…
  • 2018 American Transplant Congress

    The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients

    B. Suwelack,1 C. Sommerer,1 D. Dragun,1 O. Witzke,1 C. Hugo,1 N. Kamar,2 P. Merville,2 A. Hauser,1 P. Schenker,1 M. Junge,3 B. Nashan,1 F. Thaiss.1

    1Athena Study Group, Germany; 2Athena Study Group, France; 3Novartis, Pharma, Germany.

    The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic…
  • 2018 American Transplant Congress

    Novel Low Dosing of Rabbit Antithymocyte Globulin Preserves Excellent Outcomes and Improves the Value of Care in Low Risk Renal Transplantation

    J. Dann, W. Ally, M. Bradley, J. Geyston, A. Agarwal.

    University of Virginia Health System, Charlottesville, VA.

    Elderly and non-sensitized renal transplant patients may benefit from lesser induction immunosuppression. This study evaluates three year clinical outcomes of a low risk renal transplant…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences